Weight Loss Drugs: What You're Not Hearing About GLP-1 And GIP Based Injectables For Weight Loss
Discussions on weight loss have been going on for decades, but the discussion has evolved significantly in the last few years. Increasingly, people are turning to weight loss alternatives like injections, moving beyond just diet and exercise regimens. In this trend GLP-1-based injectables—which help manage blood sugar and support weight loss are becoming increasingly popular. While these injections may seem like an easy and almost immediate fix, an important part of the conversation is often left out: the need for careful eligibility assessment, continuous medical oversight, and safety concerns. These discussions leave out the real reasons behind why we gain weight, and the impact of our own lifestyles and habits.
Dr. Anju Ghei, MBBS, PGCRT, Head – Preventive Health, VLCC shares all you need to know:
These injectable drugs were initially approved for treating type 2 diabetes and are now also approved to manage obesity. They work by mimicking our natural hormones in the gut, GLP-1 and GIP, which help the body release insulin, slow stomach emptying, and signal a feeling of fullness, thus reducing appetite. In addition, GIP also regulates fat metabolism. By doing so, they assist in the weight loss of up to 10–20% of body weight as well as improvement in metabolic parameters. For people dealing with Type 2 diabetes, high blood pressure, high cholesterol, sleep apnoea, PCOS, or other obesity-related health issues, these beneficial effects can be truly life-changing.
But these medications are not a magic bullet, and certainly not for everyone. Clinical evidence shows that weight regain is common once the drugs are discontinued, especially when not supported by holistic lifestyle changes. Additionally, they may cause side effects such as nausea, gastrointestinal disturbances, constipation, or bloating. In rare cases, serious complications like pancreatitis, gallbladder issues, or allergic reactions may arise. Moreover, rapid weight loss itself can result in muscle loss, skin laxity, nutrient deficiencies, electrolyte imbalance, and hormonal imbalance, with symptoms like fatigue, anxiety and mood swings.
This is why careful eligibility assessment and close medical monitoring are both essential throughout the weight-loss journey.
Weight Loss: More Than Numbers
Weight loss isn't just about losing kilos, it's about rebalancing many parts of your system. That means balancing hormones, fixing your gut health, sleeping better, controlling stress, staying active and addressing emotional triggers. Injectables may get the ball rolling, but without also identifying and fixing the underlying issues, the results do not last.
These drugs must be used under proper medical guidance only, with detailed health profiling and systematic lifestyle guidance. They are most appropriate for people with certain medical conditions for which changing lifestyle alone hasn't helped.
So, What's the Alternative?
A better approach for long lasting benefits, even after the drugs are discontinued, is integrated wellness. By integrating wellness practices of nutrition (working around whole foods and conscientious calorie management), physical exercise, emotional well-being (stress reduction, behavioural therapy), and habituated lifestyle routines, this approach offers lifelong benefits. Though this pathway takes more time, discipline, and commitment, it provides something injectables can't: side-effect-free, lasting transformation. It's the best approach for those who do not have extreme metabolic disorders, desire self-control over their own health, and are not afraid to construct their own change, brick by brick.
The best strategy, therefore, is to balance both, but with expert supervision. Injectables can provide the initial thrust, but they deliver real benefits only when they are part of a tailored plan that addresses physical, emotional, and metabolic well-being.
Begin a conversation with your doctor. Monitor not only your weight, but also your energy, sleep, digestion, and mood. Long-term weight loss is about consistency, not perfection. GLP-1 Injectables might be part of the process but should not be the end goal. Real success is about taking control, gaining confidence, and achieving the energy to live life to the full, not simply shedding kilos.
view comments
Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Kim Kardashian's viral face wrap sparks medical panic over dangerous trend: Can the chin-hugging beauty fad suffocate you in your sleep?
Kim Kardashian's SKIMS Seamless Sculpt Face Wrap, promising an overnight jawline lift, has sparked controversy. Dermatologists warn the $50 mask, part of TikTok's 'ugly sleep routine,' may cause skin irritation, breathing obstruction, and worsen underlying issues. Experts question collagen claims and highlight potential dangers of combining it with trends like mouth taping. Kim Kardashian's SKIMS face wrap, promising a jawline lift, has sparked controversy. Dermatologists warn the overnight mask, part of TikTok's "ugly sleep routine," may cause skin irritation, breathing obstruction, and worsen underlying issues. Experts question collagen claims and highlight potential dangers of mouth taping, urging simpler skincare routines. Tired of too many ads? Remove Ads From TikTok fame to medical red flags Tired of too many ads? Remove Ads What's in the wrap? Collagen claims and cosmetic confusion The mouth-taping controversy Is your skincare routine trying too hard? Tired of too many ads? Remove Ads A glamorous trap for vulnerable consumers? Kim Kardashian's latest venture into the world of beauty has made waves—quite literally—around people's faces. The SKIMS Seamless Sculpt Face Wrap , launched with promises of an overnight jawline lift, has already sold out. Touted as a non-invasive alternative to surgery, it's the newest must-have in the bedtime beauty behind the viral success of the $50 chin-hugging mask is a far more sobering question: Can something designed to 'snatch your chin' do more harm than good?The wrap has become a central prop in TikTok's trending 'ugly sleep routine,' where influencers go to bed with layers of product, face tape, and now Kardashian's latest addition. While the goal is to wake up glowing and sculpted, dermatologists and sleep experts are urging Anjali Mahto, a UK-based dermatologist, told Radar Online that these wraps are 'less about results and more about performative perfection,' pointing out that the trend often stems from insecurity, not to her, the SKIMS face wrap can cause more than just skin irritation. 'It can inflame the skin barrier, obstruct breathing during sleep, and worsen underlying issues,' she warned. 'These are not medically approved treatments.'The Seamless Sculpt Face Wrap is made with polyamide, elastane, and what the brand claims is 'collagen yarn.' Fastened with Velcro and available in neutral SKIMS shades, it fits snugly from the top of the head to under the chin. The result? A compressed, sculpted look that's said to improve facial contours experts argue that the science doesn't support such claims. Dr. Yael Halaas, a facial plastic surgeon quoted in New York Post, noted the wrap mimics post-surgical compression garments—but without the regulation or medical backing. 'It lacks essential safety features like antimicrobial properties and proper moisture control,' she users are drawn in by the idea of 'collagen-infused' fabrics, but dermatologists say that's mostly marketing fluff. 'Collagen can't be absorbed through fabric. It needs to be applied topically or produced internally,' said Dr. Bindu Sthalekar of Skin Smart the wrap may provide a temporary de-puffing effect, doctors agree that lasting jawline definition requires consistent skincare, healthy habits, and sometimes in-office procedures—not an overnight the face wrap wasn't enough of a concern, its rise coincides with another trend: mouth taping. Popularized by influencers and wellness icons like Gwyneth Paltrow, the practice involves sealing your lips shut while sleeping—an act that respiratory experts warn could be deadly.'There is no proven benefit,' said Dr. Mahto. 'Anything that limits oxygen intake during sleep is potentially dangerous.'Backing this up, ENT specialist Dr. Brian Rotenberg's review of clinical studies found that mouth taping is 'medically inappropriate for most people' and can trigger serious health issues, especially for those with undiagnosed sleep apnea or breathing the physical risks, experts also criticize the emotional toll of such high-maintenance regimens. Dr. Cristina Psomadakis warned that layering active skincare ingredients or overdoing treatments—especially on young skin—can do more harm than good. 'The best nighttime routine? Just wash your face. That's usually enough,' she British Association of Dermatologists has also cautioned against using occlusive products like face wraps and overnight masks, particularly among teens and young adults. The potential consequences range from breakouts to allergic reactions and even long-term skin barrier mounting concerns, the SKIMS wrap sold out within 48 hours. Demand is so high that the brand has announced a restock. But critics argue that the product's success reflects more than market demand—it highlights how celebrity influence can overshadow medical advice.'It's being sold as self-care, but it's pushing dangerous beauty standards,' Dr. Mahto said bluntly.
Economic Times
2 hours ago
- Economic Times
Eli Lilly's experimental GLP-1 pill may rival Ozempic and Wegovy? Check how much weight you could lose
Eli Lilly's experimental weight loss pill, orforglipron, demonstrated an average weight loss of 12% in a late-stage trial, falling short of Wall Street's expectations. Despite the positive results, shares of Eli Lilly fell, while rival Novo Nordisk's shares rose. The company plans to seek regulatory approval for the pill by the end of 2025. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Eli Lily on daily GLP-1 pills Eli Lilly's weight loss pill doesn't appear to work as well as Wall Street had hoped. The drugmaker said Thursday the highest dose of its daily obesity pill helped patients lose almost 12% of their body weight, or roughly 27 pounds, at 72 weeks in a late-stage trial. The result falls on the lower end of Wall Street's of the company fell around 13% on Thursday, according to CNBC. Meanwhile, shares of rival Novo Nordisk, which is also working to bring an obesity pill to the market, jumped more than 7% on Lilly, which makes the injectable drugs Zepbound to treat obesity and Mounjaro and Trulicity to treat diabetes, is among several companies chasing an effective pill form of GLP-1s. The only such pill available so far comes with strict diet restrictions and is approved to treat says that no food or water restrictions are needed with the experimental oral medication, orforglipron, and it can be taken any time of Lilly announced that its new orforglipron pill led to an average weight loss of up to 27.3 pounds, based on results from the first of two Phase 3 trials involving over 3,100 overweight or obese adults."With orforglipron, we're working to transform obesity care by introducing a potential once-daily oral therapy that could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments," Kenneth Custer, an executive vice president and president of Lilly Cardiometabolic Health, said in a statement. "With these positive data in hand, we are now planning to submit orforglipron for regulatory review by year-end and are prepared for a global launch to address this urgent public health need."Investors had high hopes that Lilly's pill, orforglipron, would match the effectiveness of Novo Nordisk's blockbuster weight-loss injection, Wegovy . In key trials, Wegovy helped users lose around 14% to 15% of their body weight — slightly below the weight loss seen with Lilly's competing shot, Zepbound.'There was hope that this would be a wonder drug,' BMO analyst Evan Seigerman said of Lilly's pill. 'What this shows to me is that it's still a good drug, but it's bound by the limitations of being a GLP-1.'Eli Lilly said that all adults participating in its Phase 3 trials experienced weight loss while taking orforglipron. Participants on the highest dose—36 mg—lost an average of 27 pounds over 72 weeks, equating to about 12% of their body weight. While this result is significant, it falls slightly short of the weight loss typically seen with some injectable treatments with the drugmaker noticing that about 10% of participants on the highest dose chose to discontinue the weight loss, trial participants saw improvements in cardiovascular markers, including reductions in systolic blood pressure, non-HDL cholesterol, and triglycerides. Negative side effects were similar in frequency and nature to those observed with injectable GLP-1 medications. The most commonly reported side effects were mild to moderate gastrointestinal issues such as nausea, constipation, indigestion, diarrhea, and Lilly is also evaluating orforglipron's effectiveness in adults with Type 2 diabetes. In April, the company shared that the pill may help lower hemoglobin A1C levels—a key indicator of average blood sugar over two to three months—while also supporting weight Lilly aims to seek global regulatory approval for its daily oral orforglipron pill by the end of 2025, positioning itself alongside rival Novo Nordisk, which is pursuing approval for an oral form of its Wegovy (semaglutide) treatment. However, federal health regulators are expected to require more comprehensive data on the drug's safety, tolerability, and effectiveness before moving forward with any potential approval.
Mint
3 hours ago
- Mint
Acko ramps up health insurance play to expand healthcare reach
BENGALURU : Nearly a year after acquiring Better Capital-backed chronic-care startup OneCare, insurtech Acko Technology and Services Pvt. Ltd is doubling down on health insurance offerings, expanding partnerships with hospitals and clinics to tap into the growing opportunity in the space, a top executive told Mint. The Bengaluru-based unicorn acquired the digital chronic-care management company in an all-cash deal in 2024 to enter the health insurance segment. The firm, which began with auto insurance in 2016, is now working on integrating the entire process of buying health insurance—from picking a lab for medical testing to interacting with a hospital for claims. 'The problem in the health insurance industry today is that the burden of the entire process is on the customer. If there's a breakdown in the system, they're on their own. We're working towards integrating the entire system on our app and actually hand-holding customers to pick the best testing labs and hospitals," Animesh Das, managing director and chief executive of Acko General Insurance, told Mint in an interview. Acko aims to capitalize on the booming Indian healthcare sector, which is valued at over $372 billion and is growing at a compound annual growth rate of 21% since 2014, according to estimates by government think tank Niti Aayog. With health premiums already accounting for more than half of Acko's overall premium income, the firm has invested substantially to grow the segment over the last year, Das said. Acko has secured nearly $450 million in funding from investors, including Multiples PE, Accel, Elevation Capital, and General Atlantic. It was last valued at $1.1 billion in October 2021. Last week, cricketer M.S. Dhoni announced his investment in the firm and hopped on board as its brand ambassador. In the healthcare sector, Acko is in direct competition with players such as PharmEasy, HealthQuad-backed HealthifyMe, and HealthPlix that provide healthcare services such as diagnostic tests and doctor consultations. Motor insurance slowdown While Acko is yet to officially file its 2024-25 financials with the Registrar of Companies (RoC), it witnessed 'measured growth" during the year. 'It was a year of learning to know what levers will drive growth for us. Doubling down on health is a product of that learning," Das said. 'Healthcare services are a long-term game for us." The integration of its various insurance services will also result in customers engaging with the platform more regularly, which otherwise tends to be an annual activity. In the fiscal year ended March 2024, Acko's revenue climbed to ₹2,106 crore from ₹1,758 crore in the year prior, filings available with the RoC showed. Its losses narrowed marginally to ₹670 crore from ₹738 crore. Acko is among venture capital firm Elevation Capital's portfolio companies looking to get publicly listed soon. Mint reported on 6 August that the VC firm plans to take at least nine portfolio companies public over the next 12-24 months, as it gears up to monetize its portfolio amid improving public market conditions for tech and consumer startups in the country. Das declined to comment on the IPO timeline. Acko is evolving its model to keep up with a slowdown in the industry. The firm has struck a partnership with American carmaker Tesla Inc. as the insurance partner in India. 'Tesla's branding of a new-age automaker designed for young and aspirational buyers ties in well with the shift in consumer cohorts in our insurance products," Das said. A July Nuvama report said the insurance industry in India is slowing primarily due to moderation in auto sales and a drop in corporate renewal policies. Motor insurance growth has slowed down due to weak retail motor sales. The gross direct premium income (GDPI) in the motor segment rose 6.7% in June 2025, compared to 8.2% in the year-ago period.
